SPA
CATX icon

Sherbrooke Park Advisers’s Perspective Therapeutics CATX Stock Holding History

Sherbrooke Park Advisers’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$44.6K Sell
16,232
-16,193
-50% -$46.2K 0.12% 175
2025
Q3 		$111K Buy
+32,425
New +$118K 0.05% 440
2025
Q2 		– Sell
-15,000
Closed -$31.9K – 542
2025
Q1 		$31.9K Sell
15,000
-6,564
-30% -$19.7K 0.01% 560
2024
Q4 		$68.8K Buy
+21,564
New +$176K 0.02% 697

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Sherbrooke Park Advisers's CATX Position: Q4 2025 in Review

Sherbrooke Park Advisers reduced its Perspective Therapeutics (CATX) stake by 50% in Q4 2025, selling an estimated $46.2K and leaving 16,232 shares worth $44.6K. The position accounts for 0.12% of the portfolio, ranked #175.

Sherbrooke Park Advisers first reported a position in CATX in Q4 2024 and has held it in 4 quarters since. The position peaked at $111K in Q3 2025. 117 funds tracked by Wall St. Rank hold CATX as of Q4 2025.

  • Sherbrooke Park Advisers held 16,232 shares of Perspective Therapeutics worth $44.6K as of Q4 2025.
  • Sherbrooke Park Advisers sold 16,193 Perspective Therapeutics shares in Q4 2025, an estimated $46.2K.
  • Perspective Therapeutics made up 0.12% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #175 holding.
  • Sherbrooke Park Advisers first reported a position in Perspective Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Sherbrooke Park Advisers's Perspective Therapeutics position peaked at $111K in Q3 2025.
  • 117 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.